A decline in testosterone levels as men grow older is likely the result — not the cause — of deteriorating general health, say Australian scientists, whose new study finds that age, in itself, has no effect on testosterone level in healthy older men.
The results, presented June 6 at The Endocrine Society’s 93rd Annual Meeting in Boston, are the first findings released from the Healthy Man Study, according to principal investigator David Handelsman, MD, PhD, professor and director of the ANZAC Research Institute at the University of Sydney.
“Some researchers believe that an age-related testosterone deficiency contributes to the deteriorating health of older men and causes nonspecific symptoms, such as tiredness and loss of libido,” he said.
Handelsman and his team, however, found that serum (blood) testosterone levels did not decline with increasing age in older men who reported being in excellent health with no symptoms to complain of.
“We had originally expected age to have an effect on serum testosterone, so the findings were a bit of a surprise,” Handelsman said.
Two study centers in Australia recruited 325 men over the age of 40 (median age, 60) who had self-reported excellent health and no symptom complaints. To test blood testosterone levels, the researchers took blood samples from the men nine times over three months. They excluded men from the study who took medications that affect testosterone.
Obesity caused a mild and clinically unimportant lowering of blood testosterone levels, the investigators reported. Age had no effect on testosterone level.
“The modest decline in blood testosterone among older men, usually coupled with nonspecific symptoms, such as easy fatigue and low sexual desire, may be due to symptomatic disorders that accumulate during aging, including obesity and heart disease,” he said. “It does not appear to be a hormone deficiency state.”
The message for patients and their doctors, Handelsman said, is “older men with low testosterone levels do not need testosterone therapy unless they have diseases of their pituitary or testes.”
This research was supported by the MBF (Medical Benefits Fund) Foundation in Sydney, which is part of the private health insurer Bupa.
Story Source:
The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by The Endocrine Society, via EurekAlert!, a service of AAAS.
